Celator Pharmaceuticals News
Most Popular Celator Pharmaceuticals Story
Celator gains $20M round for cancer drug dev
Princeton, NJ-based Celator Pharmaceuticals has closed a $20 million Series D to back its development work on new cancer therapies. Its lead drug--CPX-351 (Cytarabine:Daunorubicin) Liposome Read more...
Latest Headlines
- September 1, 2010
- July 29, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
